News

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the use of inhaled nitric oxide (iNO) with the INOpulse® DS drug-delivery system as a combination product for pulmonary arterial hypertension (PAH). An investigational new drug application (IND) for PAH was submitted to the FDA in November 2011, and the company is pursuing clinical development under this open IND.

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients in the hospital and ICU settings, today announced that Tasos G. Konidaris has joined the Company as Senior Vice President and Chief Financial Officer (CFO). Mr. Konidaris succeeds Craig Tooman, who left the Company in early 2011 to pursue other interests.

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients in the hospital and ICU settings, today announced the introduction of its next-generation drug-delivery system, the INOmax DSIR, in neonatal intensive care units (NICUs) within hospitals throughout the United States.

Ikaria, Inc. today announced the global launch of its nextgeneration drug-delivery system, the INOMAX DSIR, in neonatal intensive care units, or NICUs, within hospitals throughout Canada.

Ikaria, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted INOmax® (nitric oxide) for inhalation an additional six months of marketing exclusivity, known as “pediatric exclusivity.” The action extends exclusivity for INOmax from January 2013 to July 2013.

Ikaria, Inc. announced that it has enrolled the first patients in its pivotal Phase III trial for LUCASSIN® (terlipressin). The multi-center, randomized, placebo controlled, double-blind trial is known as the REVERSE Trial.

Ikaria, Inc. today announced that Martin Meglasson, Ph.D., will join Ikaria as Chief Science Officer. Dr. Meglasson will be responsible for activities related to early-stage drug development. He will assume his new role at the end of July.

Ikaria, Inc. today announced that Craig Tooman will join Ikaria as Senior Vice President and Chief Financial Officer (CFO). In this role, Mr. Tooman will be responsible for all financial functions of the company, as well as for information technology services.

Ikaria, Inc. today announced that Geoffrey Nichol, M.D., has been appointed Chief Medical Officer. In this newly created role, Dr. Nichol will be responsible for activities related to late-stage drug development.

Ikaria, Inc. today announced that Douglas Greene, M.D., has been appointed Executive Vice President of Research and Development (R&D). In this role, Dr. Greene will be responsible for drug-development activities, including pre-clinical and clinical research, translational science, regulatory affairs, clinical pharmacology, pharmacovigilance, medical affairs, and project and portfolio management.